Incyte Corporation
INCY
NASDAQ·Healthcare·Biotechnology·Mkt cap $25.7B
$126.75
▼ -0.98%
P/E
15.92
Mkt Cap
$25.7B
52-Wk Range
$81.09–$132.60
52-Week Range
$81.09 - $132.60
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 46.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary drug discovery platform
- Diverse clinical-stage product pipeline
- Strategic pharmaceutical collaborations
- Focus on precision medicine technologies
Bear Case
2 risks
- Low volatility (beta 0.8).
- Significant premium - growth priced in
Growth
Stable outlook
Expanding oncology treatment portfolio
Value
Significant premium - growth priced in
Momentum
Hot
+25.9% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying INCY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 28, 2026
Reported EPS of $3.09 vs $2.15 consensus (+43.7% surprise). Revenue of $1.7B vs $1.5B expected (+11.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+43.7%
Revenue trend · last 8Q
—
+16%
+20%
+16%
+20%
+28%
+21%
+38%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.1B
$1.2B
$1.1B
$1.2B
$1.4B
$1.5B
$1.3B
$1.7B
Margins · last 8Q
Gross
93.7%
Operating
41.7%
Profit
35.0%
Wall Street consensus
13 analysts · 38% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
38%
Hold
62%
Sell
0%
Median Price Target
—
Latest: BMO Capital · Sep 1, 2026
vs Industry
How INCY stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related